EMA rethinks stance, committee now recommends Leqembi for Alzheimer’s disease
The European Medicines Agency (EMA) has reversed its stance on Biogen and Eisai’s Alzheimer’s therapy, Leqembi (lecanemab), now recommending its…
The European Medicines Agency (EMA) has reversed its stance on Biogen and Eisai’s Alzheimer’s therapy, Leqembi (lecanemab), now recommending its…